a-121

A 121 is a non-polyene antifungal antibiotic. It is active against a number of filamentous fungi including some plant and human pathogens.

A-1211212 (BCL2-IN-1) is a potent and selective Bcl-2 inhibitor. It promotes lymphocyte apoptosis, alters colonic mucosa in mice, and improves inflammation.

SKA-121 is a selective KCa3.1 activator (EC50s: 109 nM and 4.4 μM for KCa3.1 and KCa2.3, respectively).

A-1210477-piperazinyl is a compound that specifically targets and binds to the protein myeloid cell leukemia 1 (MCL1) [myeloid cell leukemia 1]. This compound is utilized in PROTAC technology, harnessing the ability to selectively degrade target proteins.

A-1210477 is an effective and specific MCL-1 and Bcl-2 inhibitor (Ki/IC50: 0.454/26.2 nM).

ICA-121431 (2,2-Diphenyl-N-[4-(thiazol-2-ylsulfamoyl) is a nanomolar potent small molecule Nav1.7 channel inhibitor with IC50 of 19 nM for rat Nav1.7, with little or no activity against human Nav1.5 or Nav1.7 channels.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.

Paclitaxel (Taxol) is a natural product and a microtubule polymer stabilizer. Paclitaxel has anti-tumor activity and causes cell death by inducing mitotic arrest, apoptosis, and cell autophagy.

ADTL-SA1215 is a selective SIRT3 activator with SIRT3 deacetylase activity that inhibits the proliferation and migration of human breast cancer MDA-MB-231 cells through the SIRT3-driven autophagy/mitochondrial autophagy signaling pathway, and can be used in the study of triple negative breast cancer.

MDL-104168 is a macrocyclic HIV-protease inhibitor.

Ociperlimab (BGB-A1217) is a novel humanized monoclonal antibody targeting TIGIT that exhibits antitumor activity. Ociperlimab blocks the TIGIT/PVR signaling pathway with high affinity and, through its Fc effector functions, synergistically enhances antitumor immune responses via multiple mechanisms. Ociperlimab is indicated for the treatment of advanced solid tumors.

Anti-IL-12 p70 Antibody (20C2) is an anti-human IL-12 p70 monoclonal antibody of the IgG1 isotype, and it acts by suppressing the production of interferon-gamma. Anti-IL-12 p70 Antibody (20C2) is applicable for research studies investigating inflammatory conditions where IL-12 signaling contributes to disease pathogenesis. Anti-IL-12 p70 Antibody (20C2) is recommended to be paired with an appropriate isotype control, specifically Rat IgG1 kappa, Isotype Control.

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is an IgG2a, κ inhibitory antibody derived from mice, specifically targeting murine CD40L/CD154.

Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an IgG antibody inhibitor derived from American hamster, specifically targeting mouse Jagged 2.

Anti-MouseIL-12Antibody (R1-5D9) is an IgG2a antibody inhibitor derived from rats, designed to target and inhibit mouse IL-12.

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-Mouse CD73 Antibody (TY/23) is an IgG2a, κ antibody inhibitor derived from rats, targeting mouse CD73.

Anti-Mouse MAdCAM-1 Antibody (MECA-367) is a rat-derived IgG2a, κ antibody inhibitor targeting mouse MAdCAM-1.

Anti-Canine CD34 Antibody (1H6) is an IgG1, κ antibody inhibitor derived from mice and targets canine CD34.

Anti-Mouse GITR (D265A) Antibody (DTA-1) targets the mouse GITR.

Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is an IgG2a, κ inhibitor antibody derived from mice and targets mouse CD16/CD32.

Anti-Rat CD8α Antibody (OX-8) is an IgG1, κ antibody inhibitor derived from mice, designed to target and inhibit rat CD8α.

AT-121 is a dual μ-opioid and neuropeptide receptor partial agonist (Kis 16.49 and 3.67 nM, respectively). It stimulates [35S]GTPγS binding to cell membranes expressing either μ-opioid receptors or neuropeptide receptors (EC50s of 19.6 and 34.7 nM, respectively.) AT-121 (0.003-0.03 mg/kg) reduced capsaicin-induced thermal anisocoria in a dose-dependent manner, but did not increase scratching activity in rhesus monkeys. In rhesus monkey drug self-administration tests, AT-121 at doses of 0.3 to 10 μg/kg per injection lacked reinforcing effects (a potential marker of abuse) and did not reduce the reinforcing effects of food pellets.AT-121 (0.01 or 0.03 mg/kg) did not induce hyperalgesia, a marker of tolerance, in rhesus monkeys.AT-121 is a safe non-addictive pain reliever with anti-injury and analgesic effects.

MB-07729 is a potent non-competitive inhibitor of fructose-1,6-bisphosphate with IC50 values of 189, 121 and 31 nM in rat, monkey and human, respectively, for the study of diabetes.